IGC Pharma, Inc.

IGC Pharma, Inc.

IGC Pharma, Inc. is a publicly traded pharmaceutical company (NYSE American: IGC) that develops therapeutics derived from cannabinoids. The firm was founded in 2005 and is headquartered in Maryland, though its operational history includes a shift from a broader cannabis strategy to a targeted CNS drug development pipeline. The underlying wealth originates from public shareholders, not a single family or fortune. The firm's primary focus is on IGC-AD1, a synthetic cannabinoid formulation in Phase 2 clinical trials for agitation in Alzheimer's disease (per company filings, 2023). It also maintains a pipeline of preclinical candidates targeting neuroinflammation and pain. IGC Pharma funds operations through equity offerings, including a $2.3 million registered direct offering closed in April 2024. As of 2025, the company had a market capitalization below $50 million and reported cash and equivalents of approximately $5.1 million in its most recent 10-Q filing. The firm employs fewer than 20 full-time staff, with a scientific advisory board including neurology specialists. It operates out of a single office in Rockville, Maryland. IGC Pharma's structural differentiator is its status as a publicly traded biotech with a THC-free synthetic cannabinoid platform — an unusual asset class for a micro-cap public company. The firm does not cultivate or distribute cannabis; it uses isolated synthetic analogs to pursue FDA approvals, a regulatory posture that separates it from the broader cannabis industry.